Avacta Group PLC - Oversubscribed Strategic Equity Fundraise of £9m
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF
FOR IMMEDIATE RELEASE
Avacta Group plc
Oversubscribed Strategic Equity Fundraise of
Funds to be used for Convertible Bond repayments
The Company has conditionally placed 12,792,859 new ordinary shares of
"This Placing enables Avacta to retain the value of our equity while further reinforcing our financial position by reducing the outstanding debt in the Convertible Bond. Our cash runway provides sufficient funding to progress both clinical drug candidates from our industry-leading pre|CISION® technology through major clinical milestones and to move our Gen Three molecule into IND-enabling studies.
"The initial clinical data on the Gen Two program AVA6103 in late H2 2026, as well as further Phase 1 data on
Director Subscriptions
In addition to the Placing,
Background to and strategic rationale of the Equity Fundraise
As announced on
· Quarterly Convertible Bond repayments and interest in respect of
· Upon the earlier of (i) the date on which the Company publishes the data readouts of its Phase 1b trials of FAP-Dox (AVA6000) in triple negative breast cancer and (ii)
Under the terms of the Amendments, if the Deferred Repayments were to be accelerated by the Convertible Bond Holder, the Company could elect to pay in cash or via the issue of new Ordinary Shares at the predetermined reference price (based on prevailing VWAPs) for
The lowest electable reference prices for the
The Company has chosen to strategically accept new investment into the business at the Issue Price of
The net proceeds of the Placing will allow the Company to pay the Deferred Repayments in cash and, in addition, pay an additional quarterly payment in cash if required.
This Placing has allowed Avacta to have an enhanced balance sheet, and should the Deferred Repayments be accelerated and an additional quarterly repayment be paid in cash, the Convertible Bond would be reduced to approximately
-Ends-
For further information from Avacta, please contact:
|
Avacta Group plc |
via Cohesion Bureau |
|
|
|
|
Strand Hanson Limited (Nominated Adviser)
|
|
|
|
|
|
Cohesion Bureau Communications / Media / Investors
|
|
About Avacta - www.avacta.com
Avacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION®. The pre|CISION® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.
About pre|CISION®
The key aspect of pre|CISION® is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION® PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION® product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.
Background to and information on the fundraise
The Issue Price represents a discount of approximately 0% to the closing mid-market price of
The Placing has been conducted by Zeus Capital Limited ("Zeus") as sole bookrunner.
The Placing
The Placing comprises the issue of 12,792,859 Placing Shares at the Issue Price to conditionally raise approximately
The Placing will be utilising the Company's existing share allotment authorities and powers.
The Placing Shares will represent approximately 2.7 per cent. of the enlarged share capital of the Company (as enlarged by the Placing Shares) and will rank pari passu with the existing Ordinary Shares.
The Company and Zeus have entered into a placing agreement (the "Placing Agreement"). Pursuant to the terms of the Placing Agreement, Zeus as agent for the Company, has conditionally agreed to use its reasonable endeavours to procure subscribers for the Placing Shares. Zeus has conditionally placed the Placing Shares with certain investors at the Issue Price.
The Placing Agreement contains certain warranties and indemnities from the Company in favour of Zeus. The Placing is not being underwritten by Zeus nor any other person.
The Placing is conditional upon, inter alia, the Placing Agreement not having been terminated in accordance with its terms and Admission becoming effective.
The Subscription
Certain Directors, being
If any of the conditions to the Subscription are not satisfied, the Subscription Shares will not be issued and any monies received from the Subscribers will be returned to them.
The Subscription Shares will, when issued and fully paid, rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of Admission.
The Subscription will be conditional upon, inter alia, Admission occurring and the Placing Agreement not being terminated prior to Admission.
Admission and total voting rights
Application will be made to the London Stock Exchange for the admission to trading on AIM of 12,857,143 Placing Shares and Subscription shares (together the "Fundraising Shares") resulting from the Placing and Subscription (together the "Fundraising"), which is expected to occur at or around
Immediately following Admission, the Company's enlarged issued ordinary share capital will be 471,330,508 Ordinary Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Related Party Transactions
Director Participation in the Subscription
The participation of
The independent directors of the Company (being
Participation of Zeus in the Placing
Zeus subscribed for 272,025 Ordinary Shares at the Issue Price, for a consideration of
The independent directors of the Company for the purposes of assessing the Zeus Placing Participation (being
Zeus Commission
The independent directors of the Company for the purposes of assessing the Zeus Commission (being
PDMR DISCLOSURE
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail on the director's share dealing.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||||||||
|
a)
|
Name
|
i- ii- |
|||||||||
|
2
|
Reason for the notification
|
||||||||||
|
a)
|
Position/status
|
I- Chief Executive Officer II- Non-Executive Director
|
|||||||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||||||||
|
a)
|
Name
|
Avacta Group Plc |
|||||||||
|
b)
|
LEI
|
2138009U3EG31OPMGH36 |
|||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||||||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 10p each in the Company
GB00BYYW9G87 |
|||||||||
|
b)
|
Nature of the transaction
|
Subscription for Ordinary Shares |
|||||||||
|
c)
|
Price(s) and volume(s)
|
Purchase of shares:
|
|||||||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
- Total Value
|
64,284
70p
|
|||||||||
|
e)
|
Date of the transaction
|
|
|||||||||
|
f)
|
Place of the transaction
|
LSE, AIM Market
|
|||||||||
Notes:
References to times in this Announcement are to
The times and dates mentioned throughout this Announcement may be adjusted by the Company in which event the Company will make an appropriate announcement to a Regulatory Information Service giving details of any revised dates and the details of the new times and dates will be notified to the London Stock Exchange and, where appropriate, Shareholders. Shareholders may not receive any further written communication.
This Announcement should be read in its entirety. In particular, the information in the "Important Notices" section of this Announcement should be read and understood.
Important Notices
This Announcement has been issued by, and is the sole responsibility of, the Company.
Zeus, which is authorised and regulated by the Financial Conduct Authority in the
Strand Hanson Limited, which is authorised and regulated by the Financial Conduct Authority in the
This Announcement does not constitute, or form part of, a prospectus relating to the Company, nor does it constitute or contain any invitation or offer to any person, or any public offer, to subscribe for, purchase or otherwise acquire any shares in the Company or advise persons to do so in any jurisdiction, nor shall it, or any part of it form the basis of or be relied on in connection with any contract or as an inducement to enter into any contract or commitment with the Company. In particular, the Fundraising Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended (the "Securities Act") or qualified for sale under the laws of any state of
The distribution or transmission of this Announcement and the offering of the Fundraising Shares in certain jurisdictions other than the
This Announcement includes "forward-looking statements" which includes all statements other than statements of historical fact, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could" or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this Announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the AIM Rules for Companies.
All offers of the Placing Shares in the European Economic Area will be made pursuant to an exemption from the requirement to produce a prospectus under the Regulation (EU) 2017/1129. In the
No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Zeus, Strand Hanson Limited or by any of their respective representatives as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.
No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.
This Announcement does not constitute a recommendation concerning any investor's option with respect to the Placing. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this announcement and publicly available information.
The Fundraising Shares will not be admitted to trading on any stock exchange other than the AIM market of the London Stock Exchange.
Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this Announcement.
The price and value of securities can go down as well as up. Past performance is not a guide to future performance.
Information to Distributors
The distribution of this Announcement and the offering of the Placing Shares in certain jurisdictions may be restricted by law. No action has been taken by the Company, Zeus or any of their affiliates that would permit an offering of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to the Placing Shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company and Zeus to inform themselves about, and to observe, such restrictions.
Solely for the purposes of the Product Governance requirements contained within Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "
The
For the avoidance of doubt, the
Each distributor is responsible for undertaking its own target market assessment in respect of the new Fundraising Shares and determining appropriate distribution channels.
EU Product Governance Requirements
1. Solely for the purposes of the product governance requirements contained within (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"), (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II and (c) local implementing measures (together the "EU Product Governance Requirements") and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the EU Product Governance Requirements) may otherwise have with respect thereto, the Fundraising Shares have been subject to product approval process, which has determined that the Fundraising Shares are: (i) compatible with an end target market of (a) investors who meet the criteria of professional clients and (b) eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by EU Product Governance Requirements (the "EU Target Market Assessment"). Notwithstanding the EU Target Market Assessment, distributors should note that: the price of the Fundraising Shares may decline and investors could lose all or part of their investment; the Fundraising Shares offer no guaranteed income and no capital protection; and an investment in the Fundraising Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.
2. The EU Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the EU Target Market Assessment, Zeus will only procure investors who meet the criteria of professional clients and eligible counterparties.
For the avoidance of doubt, the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Fundraising Shares.
3. Each distributor is responsible for undertaking its own target market assessment in respect of the Fundraising Shares and determining appropriate distribution channels.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE